ArticleActa endocrinologica (Bucharest, Romania : 2005)
EFFECT OF PIOGLITAZONE TREATMENT ON ASPROSIN LEVELS IN PATIENTS WITH DIABETES AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MAFLD).
Article in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Blood asprosin levels have been found to be elevated in patients with type 2 diabetes and those with Metabolic Dysfunction-Associated Steatotic Liver Disease (MAFLD). MAFLD is common in individuals with diabetes. We investigated the relationship between pioglitazone treatment and asprosin levels in patients with diabetes and MAFLD. Materials and Methods: Blood samples were collected from 25 patients diagnosed with diabetes and MAFLD at the time of diagnosis and 6 months after pioglitazone treatment. Additionally, blood samples were collected from 15 healthy volunteers as controls. Results: Compared to the 6-month control after pioglitazone treatment, significant reductions were observed in glucose, HbA1c, AST, ALT, GGT, ALP, and Fib-4 scores. However, no significant difference was detected in asprosin levels. Discussion: The significant decrease in glucose, HbA1c, AST, ALT, GGT, ALP, and Fib-4 scores after pioglitazone treatment indicates that pioglitazone is effective in the treatment of both diabetes and MAFLD. The fact that asprosin levels were not different in patients with diabetes and MAFLD compared to healthy controls suggests that diabetic fatty liver occurs through mechanisms independent of asprosin. Conclusion: These results imply that while pioglitazone is effective in treating both diabetes and MAFLD, its action does not involve modulating asprosin levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.